Sotyktu, deucravacitinib
Named-patient access overview. Sotyktu is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
About Sotyktu
Sotyktu (deucravacitinib) is manufactured by Bristol Myers Squibb and indicated for Moderate-to-severe plaque psoriasis in adults. It is an oral small molecule (TYK2 inhibitor) approved by the US FDA in 2022 and may be accessible to international patients through Named Patient Program or personal-import pathways.
How Reserve Meds coordinates Sotyktu
- Patient or treating physician submits a named-patient request.
- Clinical team verifies appropriateness of Sotyktu for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific NPP / personal-import documentation is prepared.
- Sotyktu is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).
Country coverage
Reserve Meds publishes detailed country deep-dives for our most-requested medications. Sotyktu country deep-dives are not yet published; we are expanding coverage as the cohort grows. If you are pursuing Sotyktu for a patient in the UAE, Saudi Arabia, India, Egypt, Pakistan, or another market we serve, submit a request and our clinical team will match the destination to the appropriate regulatory pathway and timeline.
Reserved for you. Sotyktu is in coordination scope for the first cohort. Country-specific pricing and timing are confirmed once a coordinator reviews your case.
Start a request for Sotyktu
Submit a 60-second intake. Our clinical team will reach out as our first cohort opens with case-specific feasibility, timeline, and a formal quote.